Publication date: November 2026 Source: The Lancet Global Health, Volume 14, Issue 11 Author(s): Morten Ruhwald, Alemnew F Dagnew, Gavin Churchyard, Adam Penn-Nicholson, Puneet Dewan, Alberto L Garcia-Basteiro, Emily B Wong, Willem A Hanekom, Mark Hatherill, Reinout van Crevel, Saskia den Boon, Patricia Hall-Eidson, Rein M G J Houben, Ann M Ginsberg, Frank Cobelens, Katherine C Horton, Richard G White
Symptom-agnostic endpoints in tuberculosis vaccine efficacy trials. // The Lancet Global Health. – URL: https://www.sciencedirect.com/science/article/pii/S2214109X2600241X?dgcid=rss_sd_all
Symptom-agnostic endpoints in tuberculosis vaccine efficacy trials. The Lancet Global Health. https://www.sciencedirect.com/science/article/pii/S2214109X2600241X?dgcid=rss_sd_all
“Symptom-agnostic endpoints in tuberculosis vaccine efficacy trials.” The Lancet Global Health.
@article{article68606,
title = {Symptom-agnostic endpoints in tuberculosis vaccine efficacy trials},
journal = {The Lancet Global Health},
url = {https://www.sciencedirect.com/science/article/pii/S2214109X2600241X?dgcid=rss_sd_all}
}
ABSTRACT As leadership education continues to evolve, increasing attention has been given to fostering learners’ leadership identity, capacity, and efficacy. Drawing on collaborative conversations with 12 leadership educators...